HALO News and Press, Halozyme Therapeutics Inc. From 06/19/23

2023-06-19 07:44:24 ET Summary Halozyme Therapeutics' valuation has declined, providing a more attractive entry point for investors. The company has multiple royalty-producing products and two new ones awaiting approval in 2023. Halozyme has a strong pipeline of products in de...

Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference PR Newswire SAN DIEGO , June 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executiv...

2023-05-10 09:19:15 ET Halozyme Therapeutics ( NASDAQ: HALO ) moved ~6% higher in the pre-market Wednesday even after recording lower-than-expected financials for Q1 2023 as Piper Sandler upgraded the biotech citing its near-term outlook. Raising his recommendation on...

2023-05-09 20:50:23 ET Halozyme Therapeutics, Inc. (HALO) Q1 2023 Earnings Conference Call May 09, 2023, 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer ...

2023-05-09 16:04:28 ET Halozyme Therapeutics press release ( NASDAQ: HALO ): Q1 Non-GAAP EPS of $0.47 misses by $0.01 . Revenue of $162.14M (+38.2% Y/Y) misses by $13.38M . The 38% year-over-year increase was driven by an increase in royalty revenue primarily a...

HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire Revenue Increased 38% YOY to $162.1 million ; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue Increased 43% YOY t...

2023-04-26 15:10:00 ET Summary Equity markets started the year strong, with small cap stocks posting double digit gains through early February. The portfolio was virtually flat on a net basis (-0.06%), outpacing the R2000V’s decline of -0.7% but below the R2500V’s ri...

Halozyme To Report First Quarter 2023 Financial and Operating Results PR Newswire SAN DIEGO , April 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating res...

2023-04-24 05:37:42 ET Genmab ( GMAB ) said it is filing a review of an award dismissing its claims in the second arbitration linked to a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Th...

2023-04-21 06:55:13 ET Genmab ( GMAB ) announced an award in the second arbitration arising under a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Genmab said the arbitral tribunal d...